News | Radiation Therapy | September 11, 2019

RadCalc 3D Monte Carlo Calculations for Photons Begins Beta Testing

Beta Testing begins of RadCalc 3Dmc version 7.1.1.0 utilizing Monte Carlo 3D dose volume QA technology

RadCalc 3D Monte Carlo Calculations for Photons Begins Beta Testing

September 11, 2019 — RadCalc version 7.1 with the Monte Carlo 3-D module has been released for beta testing to members of the beta testing team. The Monte Carlo 3D module utilizes technology acquired from the McGill University inventors. This release of RadCalc 3Dmc is the second of three 3D Dose Volume second check quality assurance (QA) packages. The completion of the beta test is anticipated in four weeks. An announcement of the final release date will be provided when available for purchase.

RadCalc 3Dmc utilizes the BeamNRC-based Monte Carlo dose calculation engine, providing independent, fast, easy and accurate 3-D dose volume verification for most commonly used treatment planning systems. The RadCalc 3Dmc beta release is compatible with Varian and Elekta machines. Support for additional radiotherapy treatment machines will be available in the near future.

Monte Carlo is widely recognized as the gold standard dose calculation method. The most challenging clinical cases involving highly heterogeneous structures are analyzed with the highest accuracy and confidence. Flexible implementation options allow users to combine the uncompromised accuracy of a Monte Carlo dose calculation algorithm with the levels of speed and productivity that allow busy radiation departments to meet their workflow needs.

RadCalc 3Dmc includes RadCalc AIR (Automated Import & Report) providing a fully automated process with percent difference, dose volume histogram (DVH), Gamma, and Distance to Agreement analysis tools. RadCalc 3Dmc’s fully automated process immediately alerts users to plans that fail to pass pre-set criteria.

RadCalc 3Dmc automatically checks whether DVH objectives are met for critical structures using both the treatment planning system (TPS) and RadCalc 3Dmc dose. Any number of DVH protocols can be loaded and be compared to one another from one analysis screen within RadCalc 3Dmc. Analysis reports are automatically attached to a verified plan and sent to a workstation via email or to a directory of choice on the server.

RadCalc 3Dmc is not yet available for sale in the United States. 

For more information: www.lap-laser.com

Related Content

Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...